Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects

Vasculitis (LR Espinoza, Section Editor)
First Online:
Part of the following topical collections:
  1. Topical Collection on Vasculitis

Abstract

An increasing number of therapeutic agents have been associated with a vasculitic syndrome. This usually involves small vessels, primarily capillaries, venules, and arterioles in leukocytoclastic vasculitis, small-vessel disease similar to an antineutrophil cytoplasmic antibody-related vasculitis, or mid-sized muscular arteries in a polyarteritis-like picture. Antineutrophil cytoplasmic antibodies are present in many cases of vasculitis regardless of the size of the vessel involved. Monoclonal antibodies used to treat many autoimmune disorders have become the most common agents associated with drug-induced vasculitis. Important advances in epigenetics, genetics, and neutrophil apoptosis are providing new insights into the pathogenesis of both drug-induced vasculitis and idiopathic vasculitis. Although management has not changed significantly in the past few years where withdrawal of the offending agent is the primary intervention, increasing awareness of drug-induced vasculitis can lead to earlier diagnosis and prevention of severe organ damage and fatalities.

Keywords

Antineutrophil cytoplasmic antibodies Cocaine Drug-induced vasculitis Hydralazine Leukotrienes antagonists Levamisole Minocycline Monoclonal antibodies Propylthiouracil Rituximab Statins Tumor necrosis factor-alpha Vasculitis 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The author would like to gratefully acknowledge the assistance and patience extended to me by Dr. Ahlem A. Saleh, assistant librarian, at the Arizona Health Sciences Library.

Compliance with Ethical Standards

Conflict of Interest

The author declares that he has no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any information derived directly from human or animal subjects.

References

Papers of particular interest published recently have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Merkel PA. Drug-induced vasculitis. Rheum Dis Clin N Am. 2001;27:849–62.CrossRefGoogle Scholar
  2. 2.••
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11. Important paper that updates the nomenclature of the vasculitides utilizing recent advances in our understanding of these conditions.CrossRefPubMedGoogle Scholar
  3. 3.
    Aloush V, Litinsky I, Caspi D, Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum. 2006;36:4–9.CrossRefPubMedGoogle Scholar
  4. 4.
    ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002;36:130–47.CrossRefPubMedGoogle Scholar
  5. 5.
    Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol. 2008;20:35–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Doyle MK, Cuellar ML. Drug-induced vasculitis. Expert Opin Drug Saf. 2003;2:401–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Waller R, Ahmed A, Patel I, Luqmani R. Update on the classification of vasculitis. Best Pract Res Clin Rheum. 2013;27:3–17.CrossRefGoogle Scholar
  8. 8.
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Kallenberg CG. Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol. 2014;10:484–93.CrossRefPubMedGoogle Scholar
  10. 10.•
    Radic M, Kaplan MJ. Jumbled NETs promote vasculitis. Arthritis Rheum. 2012;64:3498–501. Well-crafted editorial that describes a new form of apoptosis consisting of the formation of neutrophil extracellular nets and their possible role in the presentation of autoantigens to the immune system.CrossRefPubMedGoogle Scholar
  11. 11.
    Radic M, Martinovic Kaliterna D, Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12–7.PubMedGoogle Scholar
  12. 12.
    Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science. 1994;266:810–3.CrossRefPubMedGoogle Scholar
  13. 13.
    Denissen NH, Peters JG, Masereeuw R, Barrera P. Can sulfasalazine therapy induce or exacerbate Wegener’s granulomatosis? Scand J Rheumatol. 2008;37:72–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Ralston DR, Marsh CB, Lowe MP, Wewers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors. J Clin Invest. 1997;100:1416–24.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Altorok N, Sawalha AH. Epigenetics in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25:569–76.CrossRefPubMedGoogle Scholar
  16. 16.
    Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol. 2006;176:7143–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 2003;48:746–56.CrossRefPubMedGoogle Scholar
  18. 18.
    Ciavatta DJ, Yang J, Preston GA, Badhwar AK, Xiao H, Hewins P, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest. 2010;120:3209–19.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets. 2013;13:379–99.CrossRefPubMedGoogle Scholar
  20. 20.•
    Pendergraft 3rd WF, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014;26:42–9. Excellent review of ANCA-related vasculitis.CrossRefPubMedGoogle Scholar
  21. 21.
    Liang D, Shen N. MicroRNA involvement in lupus: the beginning of a new tale. Curr Opin Rheumatol. 2012;24:489–98.CrossRefPubMedGoogle Scholar
  22. 22.•
    Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973–90. Important introduction on the role of microRNAs in vascular inflammation and its potential importance in vasculitis.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Finlay AY, Statham B, Knight AG. Hydrallazine-induced necrotising vasculitis. Br Med J (Clin Res Ed). 1981;282:1703–4.CrossRefGoogle Scholar
  24. 24.
    Jagiello P, Gross WL, Epplen JT. Complex genetics of Wegener granulomatosis. Autoimmun Rev. 2005;4:42–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Willcocks LC, Lyons PA, Rees AJ, Smith KG. The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther. 2010;12:202.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Wieczorek S, Holle JU, Epplen JT. Recent progress in the genetics of Wegener’s granulomatosis and Churg-Strauss syndrome. Curr Opin Rheumatol. 2010;22:8–14.CrossRefPubMedGoogle Scholar
  27. 27.
    Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214–23.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176:231–41.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15:623–5.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.••
    Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi T, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3779–87. Important paper that describes the alterations the occur to the neutrophil extracellular traps when mice are exposed to propylthiouracil.CrossRefPubMedGoogle Scholar
  32. 32.
    Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–63.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol. 2005;167:39–45.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87:4115–9.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Pamies A, Castro S, Poveda MJ, Fontova R. Leucocytoclastic vasculitis associated with golimumab. Rheumatology (Oxford). 2013;52:1921–3.CrossRefGoogle Scholar
  36. 36.
    Parekh K, Ching D, Rahman MU, Stamp LK. Onset of Wegener’s granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event? Rheumatology (Oxford). 2010;49:1785–7.CrossRefGoogle Scholar
  37. 37.
    Sakaue S, Sumitomo S, Kubo K, Fujio K, Yamamoto K. Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2014;53:1529–30.CrossRefGoogle Scholar
  38. 38.
    Shibata S, Asano Y, Sato S. Cutaneous polyarteritis nodosa localized to the arm receiving an infusion of abatacept. Eur J Dermatol. 2013;23:738–9.PubMedGoogle Scholar
  39. 39.•
    Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc. 2012;87:739–45. Very good study comparing a single U.S. center with larger European multicenter studies of TNF inhibitors and vasculitis.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Ramos-Casals M, Brito-Zeron P, Cuadrado MJ, Khamashta MA. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep. 2008;10:442–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73:710–3.CrossRefPubMedGoogle Scholar
  42. 42.
    Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955–8.PubMedGoogle Scholar
  43. 43.
    Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents. A double-edged sword? Autoimmun Rev. 2010;9:188–93.CrossRefPubMedGoogle Scholar
  44. 44.
    Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves’ disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf). 2001;54:651–4.CrossRefGoogle Scholar
  45. 45.
    Yazisiz V, Ongut G, Terzioglu E, Karayalcin U. Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int J Clin Pract. 2010;64:19–24.CrossRefPubMedGoogle Scholar
  46. 46.
    Tu YL, Tsai YC, Huang JL, Yao TC. Occult pulmonary hemorrhage as a rare presentation of propylthiouracil-induced vasculitis. Pediatrics. 2011;127:e245–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Chen M, Gao Y, Guo XH, Zhao MH. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol. 2012;8:476–83.CrossRefPubMedGoogle Scholar
  48. 48.
    Tsuboi K, Ishihara Y, Ishikawa M, Tsuchida Y, Nagasawa K, Watanabe N, et al. Unusual oral ulceration, skin rash, and fever in a patient receiving propylthiouracil. Thyroid. 2009;19:421–2.CrossRefPubMedGoogle Scholar
  49. 49.
    Ozkok A, Kaya S, Elcioglu OC, Odabas AR. Propylthiouracil-induced cryoglobulinemic vasculitis. Intern Med. 2013;52:2011–2.CrossRefPubMedGoogle Scholar
  50. 50.
    Wakamatsu K, Mitsuhashi Y, Yamamoto T, Tsuboi R. Propylthiouracil-induced antineutrophil cytoplasmic antibody positive vasculitis clinically mimicking pyoderma gangrenosum. J Dermatol. 2012;39:736–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Ozkok A, Salman S, Agan M, Yavuz AS, Yarman S, Boztepe H, et al. Propylthiouracil induced anti-neutrophil cytoplasmic antibody-associated vasculitis with bone marrow plasmacytosis and granulocytopenia. Chin Med J (Engl). 2009;122:1112–4.Google Scholar
  52. 52.
    Cuellar ML. Drug-induced vasculitis. Curr Rheumatol Rep. 2002;4:55–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Chen YX, Zhang W, Chen XN, Yu HJ, Ni LY, Xu J, et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis versus primary ANCA-associated renal vasculitis: a comparative study. J Rheumatol. 2012;39:558–63.CrossRefPubMedGoogle Scholar
  54. 54.
    Ahmed K, Rao S, Simha V. Antineutrophil cytoplasmic antibody-positive vasculitis in a patient with graves disease: cross-reaction between propylthiouracil and methimazole. Endocr Pract. 2010;16:449–51.CrossRefPubMedGoogle Scholar
  55. 55.
    Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxford). 2008;47:1515–20.CrossRefGoogle Scholar
  56. 56.
    Waller JM, Feramisco JD, Alberta-Wszolek L, McCalmont TH, Fox LP. Cocaine-associated retiform purpura and neutropenia: is levamisole the culprit? J Am Acad Dermatol. 2010;63:530–5.CrossRefPubMedGoogle Scholar
  57. 57.•
    Khan TA, Cuchacovich R, Espinoza LR, Lata S, Patel NJ, Garcia-Valladares I, et al. Vasculopathy, hematological, and immune abnormalities associated with levamisole-contaminated cocaine use. Semin Arthritis Rheum. 2011;41:445–54. An excellent study of four cases seen at their institution followed by a thorough literature review of levamisole-contaminated cocaine use.CrossRefPubMedGoogle Scholar
  58. 58.
    Wolford A, McDonald TS, Eng H, Hansel S, Chen Y, Bauman J, et al. Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. Drug Metab Dispos. 2012;40:1067–75.CrossRefPubMedGoogle Scholar
  59. 59.
    Lee BL, Stone JH, Gimbel D, Khosroshahi A. A 44-year-old woman with cutaneous bullae and extensive skin necrosis. Arthritis Care Res (Hoboken). 2010;62:1805–11.CrossRefGoogle Scholar
  60. 60.
    Espinoza LR, Perez AR. Cocaine-induced vasculitis: clinical and immunological spectrum. Curr Rheumatol Rep. 2012;14:532–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Wiesner O, Russell KA, Lee AS, Jenne DE, Trimarchi M, Gregorini G, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum. 2004;50:2954–65.CrossRefPubMedGoogle Scholar
  62. 62.
    Magro CM, Wang X. Cocaine-associated retiform purpura: a C5b-9-mediated microangiopathy syndrome associated with enhanced apoptosis and high levels of intercellular adhesion molecule-1 expression. Am J Dermatopathol. 2013;35:722–30.CrossRefPubMedGoogle Scholar
  63. 63.•
    Trimarchi M, Bussi M, Sinico RA, Meroni P, Specks U. Cocaine-induced midline destructive lesions—an autoimmune disease? Autoimmun Rev. 2013;12:496–500. The association of ANCA in patients with severe midline destructive lesions from cocaine insufflation suggests that an immune component may play an important role in the development of these lesions.CrossRefPubMedGoogle Scholar
  64. 64.
    Tsai MH, Yang JH, Kung SL, Hsiao YP. Levamisole-induced myopathy and leukocytoclastic vasculitis: a case report and literature review. Dermatol Ther. 2013;26:476–80.CrossRefPubMedGoogle Scholar
  65. 65.
    Olives T, Kornas RL, Cole JB. An unexpected course and late complication of cocaine-related ANCA vasculitis. Clin Toxicol. 2014;52:707–8.Google Scholar
  66. 66.
    Hess E. Drug-related lupus. N Engl J Med. 1988;318:1460–2.CrossRefPubMedGoogle Scholar
  67. 67.
    Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum. 2000;43:405–13.CrossRefPubMedGoogle Scholar
  68. 68.
    Thakur K, Bergman M, Zaveri S, Lamore R, Vashisht R, Frederique P. Hydralazine-induced vasculitis manifesting in alveolar hemorrhage. Crit Care Med. 2014;42:A1637.CrossRefGoogle Scholar
  69. 69.
    Sangala N, Lee RW, Horsfield C, Goldsmith DJ. Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe. Int Urol Nephrol. 2010;42:503–6.CrossRefPubMedGoogle Scholar
  70. 70.
    Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19:338–47.CrossRefPubMedGoogle Scholar
  71. 71.
    O’Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum. 2001;44:2235–41.CrossRefPubMedGoogle Scholar
  72. 72.
    Eichenfield AH. Minocycline and autoimmunity. Curr Opin Pediatr. 1999;11:447–56.CrossRefPubMedGoogle Scholar
  73. 73.•
    Kermani TA, Ham EK, Camilleri MJ, Warrington KJ. Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. Semin Arthritis Rheum. 2012;42:213–21. A single-center study of nine patients with polyarteritis nodosa-like vasculitis associated with minocycline.CrossRefPubMedGoogle Scholar
  74. 74.
    Thaisetthawatkul P, Sundell R, Robertson CE, Dyck PJ. Vasculitic neuropathy associated with minocycline use. J Clin Neuromuscul Dis. 2011;12:231–4.CrossRefPubMedGoogle Scholar
  75. 75.
    Lyon TD, Ferroni MC, Casella DP, D’Agostino LA, Jackman SV. Segmental testicular infarction due to minocycline-induced antineutrophil cytoplasmic antibody-positive vasculitis. Urology. 2014;84:e1–2.CrossRefPubMedGoogle Scholar
  76. 76.
    Lenert P, Icardi M, Dahmoush L. ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review. Clin Rheumatol. 2013;32:1099–106.CrossRefPubMedGoogle Scholar
  77. 77.
    Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol. 1996;35:958–64.CrossRefPubMedGoogle Scholar
  78. 78.
    Niles J. Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. Clin Exp Immunol. 2011;164:27–30.PubMedCentralCrossRefPubMedGoogle Scholar
  79. 79.
    Kandula P, Kouides PA. Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol. 2006;142:246–7.CrossRefPubMedGoogle Scholar
  80. 80.
    Kim MJ, Kim HO, Kim HY, Park YM. Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol. 2009;36:284–7.CrossRefPubMedGoogle Scholar
  81. 81.
    Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab-induced vasculitis. Dermatology. 2001;203:83–4.CrossRefPubMedGoogle Scholar
  82. 82.
    Arulkumaran N, Suleman R, Cecconi M, Kiely P, Chua F. Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Rheumatol. 2012;18:39–41.CrossRefPubMedGoogle Scholar
  83. 83.
    Sene D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60:3848–55.CrossRefPubMedGoogle Scholar
  84. 84.
    Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63:677–82.CrossRefPubMedGoogle Scholar
  85. 85.
    Lipworth BJ, Wilson AM. Montelukast and Churg-Strauss syndrome. Thorax. 2001;56:244.PubMedCentralCrossRefPubMedGoogle Scholar
  86. 86.
    Cuchacovich R, Justiniano M, Espinoza LR. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin Rheumatol. 2007;26:1769–71.CrossRefPubMedGoogle Scholar
  87. 87.
    Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4:341–53.PubMedCentralCrossRefPubMedGoogle Scholar
  88. 88.
    Haroon M, Devlin J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol. 2008;27 Suppl 2:S75–7.CrossRefPubMedGoogle Scholar
  89. 89.
    Kalra A, Yokogawa N, Raja H, Palaniswamy C, Desai P, Zanotti-Cavazzoni SL, et al. Hydralazine-induced pulmonary-renal syndrome: a case report. Am J Ther. 2012;19:e136–8.CrossRefPubMedGoogle Scholar
  90. 90.
    Gonen KA, Erfan G, Oznur M, Erdogan C. The first case of Henoch-Schonlein purpura associated with rosuvastatin: colonic involvement coexisting with small intestine. BMJ Case Rep. 2014;2014.Google Scholar
  91. 91.
    Gunton JE, Stiel J, Caterson RJ, McElduff A. Clinical case seminar: anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab. 1999;84:13–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Division of RheumatologyUniversity of Arizona College of MedicineTucsonUSA

Personalised recommendations